Explore 3 Stock Ideas & Industry Insights Download Free Report

60 Degrees Pharmaceuticals, Inc. Common Stock

Company price
0.4682 USD -0.03 ( 6.36%)
Last update at 2026-11-20T21:00:00Z
VOLUME
51281
Market Cap
2.98M

Momentum Score

…

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.46
Low
0.50
High
52 Week Price Range
0.84
Low
7.36
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.50
Dividend Yield
-
Revenue TTM
1.21M
Revenue Per Share
0.76
Gross Profit TTM
-2.06M
Debt / Equity
0.04
ROE
-332.85%
Net Debt
-1.36M
ROCE
-208.90%
Diluted EPS TTM
-2.50

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.37M -7.96M -3.81M -6.18M -4.26M
Minority interest 0.00M 0.01M 0.01M -0.00M 0.01M
Net income -7.37M -7.95M -3.77M -6.18M -4.25M
Selling general administrative 6.28M 5.02M 4.24M 1.30M 1.12M
Gross profit 0.22M 0.22M -0.22M -0.21M 0.31M
Reconciled depreciation 0.08M 0.06M 0.10M 0.08M 0.07M
Ebit -7.36M -7.95M -1.53M -1.79M -1.09M
Ebitda -7.28M -7.88M -1.43M -1.71M -1.01M
Depreciation and amortization 0.08M 0.06M 0.10M 0.08M 0.07M
Operating income -7.76M -9.71M -5.15M -1.75M -1.12M
Other operating expenses 8.76M 10.32M 5.41M 1.97M 2.28M
Interest expense 0.01M 0.01M 2.29M 3.99M 3.17M
Tax provision 0.00M 0.00M -0.00M 0.00M 0.00M
Net interest income -0.01M -0.01M -3.39M -3.99M -3.17M
Income tax expense - 0.00M 0.00M 0.00M 0.00M
Total revenue 1.01M 0.61M 0.25M 0.22M 1.16M
Total operating expenses 7.98M 9.94M 4.93M 1.54M 1.43M
Cost of revenue 0.78M 0.38M 0.47M 0.43M 0.85M
Total other income expense net 0.39M 1.76M 1.34M -0.44M 0.04M
Net income from continuing ops -7.37M -7.96M -3.44M -6.18M -4.26M
Net income applicable to common shares - - - -6.18M -6.18M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5.37M 5.76M 7.78M 1.30M 1.39M
Intangible assets 0.22M 0.16M 0.23M 0.16M 0.11M
Other current assets 0.98M 1.07M 4.40M 0.20M 0.22M
Total liab 1.99M 1.80M 2.99M 25.45M 19.55M
Total stockholder equity 3.46M 4.04M 4.87M -23.58M -17.58M
Other current liab 0.37M 0.64M 2.31M 1.69M 0.00M
Common stock 0.00M 0.00M 0.00M 0.00M 4.98M
Capital stock 9.57M 9.57M 9.86M 0.00M 4.98M
Retained earnings -47.89M -40.53M -32.58M -28.82M -22.63M
Other liab - - - 0.26M -
Cash 1.51M 1.66M 2.14M 0.26M 0.12M
Total current liabilities 1.84M 1.66M 2.84M 23.92M 0.64M
Current deferred revenue - - - 0.33M -0.00M
Net debt -1.36M -1.50M -1.97M 22.15M 18.69M
Short term debt 0.01M 0.01M 0.02M 21.15M 0.05M
Short long term debt 0.01M 0.01M 0.01M 21.14M -
Short long term debt total 0.15M 0.16M 0.17M 22.42M 18.80M
Other stockholder equity 41.65M 34.86M 27.46M 5.16M -
Property plant equipment - - - - 0.11M
Total current assets 4.90M 5.39M 7.24M 1.10M 1.18M
Net tangible assets - - - -23.74M -17.69M
Short term investments 1.24M 1.73M - - -
Net receivables 0.51M 0.49M 0.23M 0.05M 0.15M
Long term debt 0.14M 0.15M 0.15M 1.27M 18.74M
Inventory 0.66M 0.44M 0.47M 0.52M 0.69M
Accounts payable 1.46M 1.01M 0.51M 0.76M 0.59M
Accumulated other comprehensive income 0.14M 0.14M 0.14M 0.07M 0.08M
Non currrent assets other - 0.07M 0.24M - -
Non current assets total 0.47M 0.37M 0.54M 0.20M 0.22M
Capital lease obligations - 0.00M 0.01M 0.01M 0.06M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.47M -1.89M -0.11M -0.06M -0.04M
Change to liabilities - - - 0.00M -0.84M
Total cashflows from investing activities 0.25M -1.89M -0.12M -0.06M -0.06M
Net borrowings - 0.00M -0.96M - 0.61M
Total cash from financing activities 6.44M 7.05M 6.47M 1.22M 0.61M
Net income -7.37M -7.96M -3.77M -6.18M -4.26M
Change in cash -0.15M -0.48M 1.88M 0.15M -0.08M
Begin period cash flow 1.66M 2.14M 0.26M 0.12M 0.19M
End period cash flow 1.51M 1.66M 2.14M 0.26M 0.12M
Total cash from operating activities -6.85M -5.65M -4.54M -1.01M -0.65M
Issuance of capital stock 6.45M 7.04M 6.45M - -
Depreciation 0.08M 0.06M 0.10M 0.08M 0.07M
Other cashflows from investing activities 0.25M -0.08M -0.06M - -
Change to inventory -0.47M 0.02M 0.21M -0.05M 0.31M
Change to account receivables -0.02M -0.26M -0.19M 0.10M 0.71M
Other cashflows from financing activities -0.02M 0.01M 0.98M 1.22M 0.68M
Change to netincome - - - 0.62M 0.62M
Capital expenditures 0.22M 0.18M 0.12M 0.06M 0.04M
Change in working capital -0.01M 0.19M 0.41M 3.31M 2.90M
Stock based compensation 0.46M 3.61M 1.52M - -
Other non cash items -0.01M -1.56M -1.28M 1.78M 0.64M
Free cash flow -7.07M -5.83M -4.66M -1.07M -0.68M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SXTP
60 Degrees Pharmaceuticals, Inc. Common Stock
-0.03
6.36%
0.47 - - 2.45 - 10.74 22.23
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

60 Degrees Pharmaceuticals, Inc. Common Stock

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.

1025 Connecticut Avenue NW, Washington, DC, United States, 20036

202 327 5422

3

Name Title Year Born
Dr. Geoffrey Stuart Dow Chairman, CEO & President 1974
Mr. Tyrone Miller CFO & Treasurer 1975
Dr. Bryan Smith Chief Medical Officer 1966
Ms. Kristen Landon Chief Commercial Officer 1967
Ms. Jennifer Herz Director NA
Dr. Geoffrey Stuart Dow Ph.D. Chairman, CEO & President 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…